Heart Failure Therapeutics in Asia-Pacific Markets

by Sameer Joshi or 01-Sep-2018

Heart Failure (HF) is a global pandemic, since it affects around 26 million people worldwide. 74% of HF patients are suffering from at least one co-morbidity that is more likely to worsen the patient’s overall health status. HF is also an important health problem in Asia, and its prevalence seems to be even higher compared to Western countries, ranging from 1.3% to 6.7% with an annual incidence of 0.5–1.8 million. The switch toward a Western lifestyle in developing countries may be contributing to a real HF pandemic.

Significant Unmet Need Exists in the HF Market - Publisher does not expect this unmet need to be fulfilled during the forecast period, particularly as Bayer has halted development of its next-generation mineralocorticoid receptor antagonist (MRA), finerenone, which boasted an enhanced safety profile over currently available MRAs.

However, several potassium-binding agents were approved in APAC to treat hyperkalemia and may relieve the burden of this unmet need. As well as the presence of numerous clinical unmet needs, there is a plethora of environmental problems that impact this market. These include patient compliance due to complex treatment regimens, sub-optimal dosing of HF therapies, and the disconnected management of patients, particularly after hospital discharge.

Despite international HF guidelines being updated in 2016, GBI Research expects these environmental issues to remain prominent during the forecast period.